SM
PHIO icon

Sabby Management’s Phio Pharmaceuticals PHIO Stock Holding History

Sabby Management’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,131
Closed -$86.7K – 40
2024
Q3 		$86.7K Buy
+25,131
New +$90.1K 0.05% 24
2024
Q1 		– Sell
-19,188
Closed -$131K – 68
2023
Q4 		$131K Buy
19,188
+1,850
+11% +$19K 0.13% 33
2023
Q3 		$236K Sell
17,338
-79
-0.5% -$1.64K 0.17% 31
2023
Q2 		$450K Buy
+17,417
New +$612K 0.37% 31
2021
Q4 		– Sell
-377
Closed -$83K – 205
2021
Q3 		$83K Sell
377
-102
-21% -$21.3K 0.01% 162
2021
Q2 		$117K Buy
479
+266
+125% +$65.6K 0.02% 141
2021
Q1 		$62K Buy
+213
New +$70.8K 0.01% 152
2020
Q2 		– Sell
-2,363
Closed -$452K – 119
2020
Q1 		$452K Buy
+2,363
New +$1.46M 0.19% 40
2019
Q1 		– Sell
-265
Closed -$520K – 111
2018
Q4 		$520K Buy
+265
New +$626K 0.11% 50
2018
Q3 		– Sell
-28
Closed -$325K – 145
2018
Q2 		$325K Buy
+28
New +$414K 0.05% 94
2017
Q1 		– Sell
-7
Closed -$284K – 297
2016
Q4 		$284K Buy
+7
New +$547K 0.02% 231

Other funds holding PHIO

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Sabby Management's PHIO Position: Q4 2024 in Review

Sabby Management sold out of Phio Pharmaceuticals (PHIO) in Q4 2024, closing a stake of 25,131 shares — an estimated $86.7K sold.

Sabby Management first reported a position in PHIO in Q4 2016 and held it in 11 quarters. The position peaked at $520K in Q4 2018. 11 funds tracked by Wall St. Rank hold PHIO as of Q4 2024.

  • Sabby Management reported no remaining Phio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Sabby Management sold 25,131 Phio Pharmaceuticals shares in Q4 2024, an estimated $86.7K.
  • Sabby Management first reported a position in Phio Pharmaceuticals in Q4 2016 and held it in 11 quarters.
  • Sabby Management's Phio Pharmaceuticals position peaked at $520K in Q4 2018.
  • 11 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2024.

Based on Sabby Management's 13F filing for Q4 2024, filed 14 Feb 2025.